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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the diagnostic accuracy of FibroTest, transient elastography method, combined FibroTest and transient elastography
method, no matter the sequence, using liver biopsy as reference standard, for assessment of severe hepatic fibrosis and cirrhosis in adults
with chronic hepatitis C without any co-infections such as hepatitis B, HIV, and alcoholic liver disease.
• To compare the accuracy of FibroTest, transient elastography method, combined FibroTest and transient elastography method,
for assessment of hepatic fibrosis in adults with chronic hepatitis C.
• To explore heterogeneity analysing the following study factors:
◦ different grade of inflammation according to the liver biopsy;
◦ different lengths of liver biopsy sample;
◦ different number of portal tracts included in a liver biopsy sample;
◦ different serum levels of ALT activity.
• different grade of inflammation according to the liver biopsy;
• different lengths of liver biopsy sample;
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• different number of portal tracts included in a liver biopsy sample;
• different serum levels of ALT activity.
B A C K G R O U N D
Hepatic fibrosis is the main consequence of necroinflammation
in liver tissue, most often caused by chronic viral hepatitis B or
C. When fibrosis advances, it causes bridging between the portal
areas or between the portal area and the central vein, and causes
the formation of pseudo-lobule (i.e., cirrhosis develops). Hepatitis
C virus infection is a major cause of severe illness and death. The
economic burden of the disease is high. Worldwide, 130 million
to 150 million people are infected with hepatitis C virus (WHO
2014). Every year, another three to four million people acquire the
infection, and 350,000 to 500,000 people die from hepatitis C-
related liver diseases in a year (WHO 2014). About 15% to 45%
of infected people may eliminate the virus without any treatment,
but 55% to 85% of chronically infected people will develop a
chronic liver disease. About 30% to 50% of people infected with
hepatitis C virus will develop hepatic fibrosis without clinical or
laboratory symptoms of significant liver disease (Ascione 2007).
However, the progress of hepatic fibrosis to cirrhosis in people
with chronic hepatitis C is slow (Kenny-Walsh 1999;Wiese 2005).
About 15% to 30% of infected people will develop liver cirrhosis
within 20 years, and 1% to 5% of those will die from liver cirrhosis
decompensation or liver cancer (WHO 2014).
Severe fibrosis and cirrhosis should be regarded with highest pri-
ority in terms of treatment in an attempt to prevent the devel-
opment of further complications from the end stage of chronic
hepatitis C virus infection such as oesophageal bleeding, hepato-
cellular carcinoma, hepatic insufficiency, etc. So far, four classes
of direct-acting antiviral agents have become available, claiming
their ability to eradicate the hepatitis C virus, irrespective of the
stage of fibrosis (Pockros 2015). The direct-acting antiviral agents
have also led to new interpretations of the hepatitis C virus ri-
bonucleic acid (RNA) concentration results. The longer the de-
lay in diagnosing and staging correctly the hepatitis C virus, the
higher the risk of developing advanced fibrosis and the poorer the
survival prognosis (AASLD/IDSA/IAS-USA 2015; EASL 2015;
EASL-ALEH 2015).
The natural course of chronic hepatitis C virus infection depends
on age at time of infection; sex; degree of inflammation presented;
co-infection with human immunodeficiency virus (HIV) or hep-
atitis B virus infection; and co-morbid conditions such as im-
munosuppression, insulin resistance, non-alcoholic steatohepati-
tis, haemochromatosis, and schistosomiasis (Chen 2006; Ascione
2007). Approximately 80% of people with hepatitis C infection
do not exhibit symptoms, and the stage of liver disease remains
unknown (Marcellin 1999; WHO 2014).
Liver biopsy is considered reference standard for diagnosing severe
and advanced hepatic fibrosis in people with chronic hepatitis C,
who are expected to have higher benefit from treatment (Castera
2011).
Liver biopsy provides information on the degree of inflammation
and the amount of established fibrosis. Liver biopsy is obtained in
threeways: percutaneous, transjugular or transfemoral, and laparo-
scopic (Kuntz 2008). Specimens are obtained either with a core
aspiration needle (Menghini, Jamshidi, Klatskin style) or sheathed
cutting needle (Tru-Cut style) that is at least 16-gauge in calibre.
Specimens of liver tissue with a mean length of at least 15 mm
and at least seven portal tracts are among the factors that can pro-
vide reliable morphological staging of hepatic fibrosis and grading
of inflammation (Rockey 2009). As liver biopsy is painful, and
in some cases it may lead to severe complications, people are not
willing to undergo it (Castéra 2005). The accuracy of liver biopsy
may also be affected by sampling errors and intra- and interob-
server variability (Bedossa 2003). Various non-invasive methods
have been suggested and used to detect or confirm the diagnosis of
chronic hepatitis C infection (WHO 2014; EASL-ALEH 2015).
Non-invasive methods use two different approaches for diagnos-
ing stages of liver fibrosis in chronic liver disease: one based on
the quantification of biomarkers in serum blood samples (e.g., Fi-
broTest®, Forns® Index, APRI (aspartate aminotransferase (AST)
to platelet ratio index), etc.) and the other based on the measure-
ment of liver stiffness (e.g., transient elastography, ARFI (acoustic
radiation force impulse),magnetic resonance elastography (MRE),
etc.) (EASL-ALEH 2015). Guidelines suggest that blood tests in
combination with liver stiffness measurements may improve the
diagnostic accuracy when stage of hepatic fibrosis is assessed, re-
sulting in a significant reduction in the number of liver biopsies
and in a better selection of patients to be investigated with the
biopsy procedure (Castera 2011; EASL 2011).
Target condition being diagnosed
Severe hepatic fibrosis and cirrhosis in adults with chronic hepati-
tis C. The diagnosis of chronic hepatitis C includes detection of
both hepatitis C virus antibodies and hepatitis C virus RNA (lower
limit of detection less than 15 IU/mL) in the presence of biolog-
ical or histological signs of chronic hepatitis (either by elevated
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aminotransferases or by histological changes of chronic hepatitis
C) (WHO 2014; EASL 2015). We chose to study a homogeneous
group of people as pathogenesis of liver injury may be influenced
by different aetiological factors, co-infected patients may require
different treatments, and the time for progression of fibrosis into
cirrhosis.
There are a number of staging systems for evaluating hepatic fi-
brosis in people with chronic hepatitis C. METAVIR is the most
widely used scoring system for interpretation of liver biopsy results
based on the stage of fibrosis where F0 indicates no fibrosis, F1
indicates portal fibrous expansion, F2 indicates thin fibrous septa
emanating from portal triads, F3 indicates fibrous septa bridging
portal triads and central veins, and F4 indicates cirrhosis (Table
1). Hepatic fibrosis could be considered clinically significant if de-
fined as F2 or worse, using METAVIR score (Franciscus 2007).
Hepatic fibrosis could be considered clinically severe if defined as
F3 or worse, using METAVIR score (F3 and F4), which is the sub-
ject of our review. In Table 1, we have also included other widely
used systems for classification of hepatic fibrosis in people with
chronic hepatitis C (Knodell 1981; Desmet 1994; Ishak 1995;
Brunt 1999; Kleiner 2005), as liver pathologists have reached no
universal consensus on the standardisation of scoring systems.
Index test(s)
The non-invasive FibroTest and transient elastography are widely
used tests for assessment of hepatic fibrosis in people with chronic
hepatitis C (Sandrin 2003; Nahon 2008).
FibroTest (i.e., BioPredictive®, Paris, France and registered as Fi-
broSureT M in the USA), is a test for determining the stage of
hepatic fibrosis in people with chronic hepatitis C. The test uses
six serum markers for identification of the existence of fibrosis in
the liver tissue; alpha-2-macroglobulin, haptoglobin, gamma-glu-
tamyl transpeptidase (GGT), total bilirubin, apolipoprotein A1,
and alanine aminotransferase (ALT). In addition, it takes into ac-
count the age and sex of the people when defining the stage of hep-
atic fibrosis (Shaheen 2007; Gressner 2009). It can be performed
in ambulatory conditions. However, there are also disadvantages.
It is non-liver specific, is unable to discriminate between interme-
diate stages of fibrosis, has limited availability due to proprietary
rights, and can be influenced by haemolysis, Gilbert’s syndrome, or
systematic inflammation (EASL-ALEH 2015). During its evalua-
tion, the FibroTest was assessed on control liver biopsies using the
METAVIR scoring system for substantial fibrosis of F2 or worse
and activity score of the biopsy specimens (Imbert-Bismut 2001).
Transient elastography (i.e., FibroScan® equipment, Echosens,
Paris, France) is amechanical test designed tomeasure liver stiffness
in people with chronic hepatitis C virus. A probe is put on the
skin surface overlying the liver. After pressing the button on the
probe, a pulse wave is transmitted across the liver parenchyma.
After a short interval, a second ultrasound wave is transmitted.
The difference between the velocity of the two waves in the liver
parenchyma is calculated using the Doppler technique (Sandrin
2003; Nahon 2008). As it is known from physical principles, the
velocity of the pulse wave increases with the stiffness of the liver
parenchyma.
Liver stiffness is expressed as a median value in kiloPascals (kPa).
A pre-defined cut-off of 8.00 kPa is predictive of severe hepatic
fibrosis in chronic hepatitis C that is F3 or worse by theMETAVIR
scoring system (Mueller 2010). The transient elastographymethod
is simple, highly reproducible, and allows examination of at least
100 times larger volume of liver tissue than a biopsy sample (
de Lédinghen 2008). Extrahepatic cholestasis, food intake, and
excessive alcohol use are among the factors influencing transient
elastography measurements (EASL-ALEH 2015).
Clinical pathway
The first-line diagnostic test for hepatitis C virus infection is mea-
surement of hepatitis C viral antibodies. People with detectable
hepatitis C viral antibodies, before undergoing anti-viral therapy,
should have hepatitis C virus RNA levels (expressed in IU/mL)
detected and quantified by molecular tests with a lower limit of
detection of 15 IU/mL or less based on real-time reverse transcrip-
tion polymerase chain reaction methods (EASL 2015). The hep-
atitis C virus genotype, levels of transaminases, and liver synthetic
function should be assessed before start of treatment in order to
determine the appropriate treatment regimens and duration. The
severity of fibrosis should be assessed along with the presence of
any co-morbid conditions possibly influencing the progression of
the liver disease. Following EASL 2015, the stage of fibrosis us-
ing non-invasive methods should be assessed after the diagnosis of
chronic hepatitis C and before start of its treatment. However, the
stage of fibrosis using liver biopsy should be reserved for people
with advanced stage fibrosis and with suspected additional aetiolo-
gies of liver injury or in case of discordance in the results obtained
through any of the non-invasive methods (EASL 2015). Monitor-
ing of hepatitis C virus viral load is performed to guide treatment
duration, that is, to continue on therapy, or to determine whether
to stop therapy.
Transient elastography, FibroTest, or their combination are rec-
ommended as non-invasive tests for diagnosis of severe fibrosis or
cirrhosis in people with chronic hepatitis C (EASL-ALEH 2015).
Prior test(s)
Hepatitis C virus antibody, hepatitis C virus RNA test, liver func-
tion tests (ALT, AST), FibroTest alone, transient elastography
method alone, and combined FibroTest and transient elastogra-
phy method could potentially be some of the first tests that people
undergo after being diagnosed with chronic hepatitis C.
3FibroTest, transient elastography method, and combined FibroTest and transient elastography method for diagnosis of severe hepatic
fibrosis and cirrhosis in adults with chronic hepatitis C (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Role of index test(s)
FibroTest, transient elastography method, and combined Fi-
broTest and transient elastographymethod are non-invasive meth-
ods for the assessment of severe hepatic fibrosis and cirrhosis that
could be used as triage or replacement tests of liver biopsy.We have
not taken the cost-effectiveness into account when defining the
role of the listed index tests, as this is not possible in this review.
Alternative test(s)
There are different alternative non-invasivemethods formeasuring
hepatic fibrosis. Based on their principle of defining fibrosis in
people with hepatitis C virus, tests are grouped as follows:
• Based on biochemical variables: ALT and AST ratio,
prothrombin time, hyaluronic acid, platelets (aspartate
aminotransferase/platelet ratio index (APRI), Forn’s index -
combines age, GGT, cholesterol, and platelet count). The tests
are based on recordings of liver biochemical variables. All the
tests are used as surrogate markers for fibrosis, are inexpensive
laboratory tests, performed routinely in people with chronic liver
disease (Wai 2003; Degos 2010; EASL 2011).
• Ultrasound-based modalities: ARFI, and supersonic shear
imaging (SSI) (Ersoz 1999; Liu 2007).
• Magnetic resonance is another imaging method which
includes unenhanced magnetic resonance imaging (MRI), MRE,
MRI with diffusion-weighted imaging (DWI) and magnetic
resonance spectroscopy.
• Breath tests: methacetin breath test and C-aminopyrine
breath test are markers of liver fibrosis in the setting of hepatitis
C virus (Braden 2005; Lalazar 2008).
• Algorithms: several algorithms exist that combine blood tests
or FibroScan in order to improve the accuracy of detecting liver
fibrosis and cirrhosis (Sebastiani 2009; Castéra 2010; Sebastiani
2012).
A few of the mentioned alternative tests are currently being stud-
ied in Cochrane diagnostic test accuracy reviews (Kalafateli 2015;
Kalafateli 2016). However, their role and place in the clinical path-
way in terms of diagnosing people with chronic hepatitis C still
needs to be established.
Rationale
Identifying people with cirrhosis or people with advanced fibrosis
is of particular importance as their prognosis and their response
to treatment differ (EASL 2011; EASL 2015). Liver biopsy is
still regarded as the reference standard for assessing fibrosis in
people with chronic hepatitis C. The advantage of liver biopsy
for staging fibrosis in chronic hepatitis C is that this test not only
fulfils its purpose, but it may also give diagnostic information
for concurrent liver diseases such as alcoholic or non-alcoholic
steatohepatitis, autoimmune liver disease, etc. (Poulsen 1979;
Ismail 2011). Using liver biopsy for diagnosis of chronic hepatitis
C is limited by sampling error, different levels of experience of the
morphologists, invasiveness of procedure, and risk of both serious
and non-serious complications (Seeff 2010; Castera 2011).
2015 clinical recommendations refer to the use of non-invasive
serum markers (FibroTest, APRI, FIB4, etc.) and transient elas-
tography for detection of hepatic fibrosis (EASL-ALEH 2015).
It is suggested that the combined use of different non-invasive
methods would possibly reduce the necessity of liver biopsy (EASL
2011). Non-invasive methods could also be used in the follow-
up of people infected with chronic hepatitis C (Castera 2011).
However, the optimal algorithm for use of non-invasive methods
still needs to be established (Castera 2011).
We found no diagnostic test accuracy review prepared with
Cochrane methodology to determine the diagnostic test accuracy
of FibroTest, transient elastography method, combined FibroTest
and transient elastography method, no matter the sequence, using
liver biopsy as reference standard, for assessment of severe hepatic
fibrosis and cirrhosis in adults with chronic hepatitis C.
O B J E C T I V E S
To determine the diagnostic accuracy of FibroTest, transient elas-
tography method, combined FibroTest and transient elastography
method, no matter the sequence, using liver biopsy as reference
standard, for assessment of severe hepatic fibrosis and cirrhosis in
adults with chronic hepatitis C without any co-infections such as
hepatitis B, HIV, and alcoholic liver disease.
Secondary objectives
• To compare the accuracy of FibroTest, transient
elastography method, combined FibroTest and transient
elastography method, for assessment of hepatic fibrosis in adults
with chronic hepatitis C.
• To explore heterogeneity analysing the following study
factors:
◦ different grade of inflammation according to the liver
biopsy;
◦ different lengths of liver biopsy sample;
◦ different number of portal tracts included in a liver
biopsy sample;
◦ different serum levels of ALT activity.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We will include cross-sectional cohort studies, case-control stud-
ies, and randomised comparisons of test accuracy that compare Fi-
broTest, transient elastography method, and combined FibroTest
and transient elastography method to the reference standard.
We will include studies that are published in any language as full
paper articles or in the form of abstracts, published in conference
proceedings, or presented as posters.
Participants
We will include men or women aged above 18 years, with chronic
hepatitis C virus infection, in any setting (i.e., hospitalised or
ambulatory participants). The participants could have had any
stage of fibrosis, including cirrhosis.
We will not consider studies with people with recurrent hepatitis
C infection who have received a liver transplant or studies with
participants with concomitant liver diseases.
Index tests
FibroTest alone, transient elastography method alone, and a com-
bination of the FibroTest and the transient elastography method.
Target conditions
The presence of hepatic fibrosis in people with chronic hepatitis C.
Based on the METAVIR histopathological score for interpreting
liver biopsy, there are five stages of hepatic fibrosis: no fibrosis - F0;
mild fibrosis - F1; significant fibrosis - F2 or worse; severe fibrosis
- F3 or worse; cirrhosis - F4 (Table 1).
We will dichotomise the hepatic fibrosis estimated by the
METAVIR score as follows:
• we will consider people with METAVIR score of F3 or
worse ’diseased’ and people with METAVIR score of F0 plus F1
plus F2 ’non-diseased’;
• we will consider people with METAVIR score of F4
’diseased’ and people with METAVIR score of F0 plus F1 plus
F2 plus F3 ’non-diseased’.
Reference standards
Liver biopsy.
Search methods for identification of studies
We will combine electronic searches with reading references of
identified studies of possible interest.
Electronic searches
We will search The Cochrane Hepato-Biliary Group Controlled
Trials Register (Gluud 2016), The Cochrane Hepato-Biliary
Group Diagnostic Test Accuracy Studies Register (Gluud 2016),
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE (OvidSP), EMBASE (OvidSP), and the Science Ci-
tation Index Expanded (Royle 2003; de Vet 2008).
We will also read references of the retrieved citations for additional
studies of interest. We will include abstracts only if these are iden-
tified through the electronic or manual searches.
Appendix 1 shows the preliminary search strategies for the different
databases with the expected time spans for the searches. The given
search strategies may be improved at the review preparation phase.
Data collection and analysis
Selection of studies
Two review authors (CP and Ekaterina Liusina (EL) (to join at the
review stage)) will independently identify studies for possible in-
clusion in the review by reading the abstracts of the search results.
Authors will exclude references with a study design not fulfilling
the inclusion criteria of the review protocol. We will retrieve pub-
lications in full for a second selection of relevant studies. We will
identify multiple publications for inclusion and read through for
extraction of data, not provided in the earliest publication.
The studies that we will include must evaluate FibroTest, transient
elastography method, or combined FibroTest and transient elas-
tography method in the diagnosis of hepatic fibrosis stage using
liver biopsy as the reference standard. In order to provide data for
our analyses, the studies must provide data that will enable us to
calculate the true-positive (TP), false-positive (FP), true-negative
(TN), and false-negative (FN) diagnostic values of transient elas-
tography and FibroTest in diagnosing the stages of hepatic fibro-
sis, based on cut-off points for liver stiffness as described by the
authors of the identified studies.
We plan to contact authors of studies in which data are missing,
either by e-mail or letter. If we receive no reply, we will list the
study under ’Excluded studies’.
Wewill put nomaximum limit on the time interval of investigation
with liver biopsy and transient elastography and FibroTest alone
or in combination when we select the studies for inclusion in this
review. However, the accepted time interval is advised to be no
more than six months.
Data extraction and management
Three review authors (CP, EL, GC) will independently extract
data, using a data extraction sheet.
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We will collect data on study origin, year of publication, par-
ticipants’ epidemiological and laboratory characteristics, techni-
cal failures in undertaking liver biopsy and transient elastography,
cut-off values of the index tests, stage of hepatic fibrosis estimated
by histological score, and information related to the QUADAS-
2 items for evaluation of the methodological quality (Whiting
2011).
We will also extract all necessary data to calculate TP, RP, TN, and
FN values, using the reference standard of liver biopsy. If infor-
mation on any of the TP, FP, FN, and TN diagnostic test values
or results are missing, we will attempt to derive them using other
information that the study may provide. We will also attempt to
obtain missing information from authors of the included studies.
If liver biopsy samples are reported with any of the five semi-
quantitative scores (i.e., METAVIR (Franciscus 2007), Knodell
(Franciscus 2007), Ishak (Franciscus 2007), Kleiner (Kleiner
2005), Scheuer (Regev 2002)), we will use a conversion grid for
hepatic fibrosis staging adapted after Goodman 2007 (Table 1).
For grading steatosis, as zone 1 steatosis is a common distribution
in chronic hepatitis C, we will use the Nonalcoholic Steatohep-
atitis Clinical Research Network scoring system (Kleiner 2005;
Kleiner 2012) (Table 2).
Assessment of methodological quality
Design flaws in test accuracy studies can produce biased results
(Lijmer 1999; Whiting 2004; Rutjes 2006). In addition, evalua-
tion of study results is quite often impossible due to incomplete
reporting (Smidt 2005).
To limit the influence of different biases, three review authors (CP,
GC, EL), in pairs or independently of one another, will assess the
risk of bias of the included diagnostic test accuracy studies, using
QUADAS-2 domains (Whiting 2011). A fourth review author
(ET) will act as an arbitrator in case of disagreements between the
authors assessing the risk of bias of the studies. We will contact
study authors if information on methodology is lacking in order
to assess correctly the risk of bias of the studies.
Appendix 2 shows the adopted items that will wewill use to address
the participant spectrum, index test, target condition, reference
standard, and flow and timing, and which answers would also
reflect the general quality of the included studies.
QUADAS-2 is not used to generate a summary ’quality score’
because of the well-known problems associated with such scores
(Jüni 1999; Whiting 2005). If a study is judged as ’low’ on all
domains relating to bias or applicability, then it is appropriate to
have an overall judgement of ’low risk of bias’ or ’low concern
regarding applicability’ for that study. If a study is judged as ’high’
or ’unclear’ on one or more domains, then it may be judged ’at
risk of bias’ or as having ’concerns regarding applicability’.
We will use tabular and graphical displays to summarise
QUADAS-2 assessments.
Statistical analysis and data synthesis
Wewill carry out the analyses followingChapter 10 (Analysing and
Presenting Results), as recommended in the Cochrane Handbook
for Systematic Reviews of Diagnostic Test Accuracy (Macaskill 2010).
The analyses will be performed using ReviewManager 5 (RevMan
2014).
Index tests
We will build 2 × 2 tables of the FibroTest and transient elastog-
raphy performance, alone or in combination (TP, TN, FP, FN),
for each primary study and for all of the pre-defined target condi-
tions (mild hepatic fibrosis, significant hepatic fibrosis, severe hep-
atic fibrosis, and cirrhosis). We will estimate sensitivity, specificity,
positive and negative likelihood ratios (LR+ and LR-) with their
95% confidence intervals (CI). First, we will perform a graphical
descriptive analysis of the included studies: we will report forest
plots (sensitivity and specificity separately, with their 95% CIs)
and we will provide a graphical representation of the studies in the
receiver operating characteristic (ROC) space (sensitivity against
1 - specificity). Second, where appropriate, we will perform meta-
analyses. If the primary studies report accuracy estimates of tran-
sient elastography or FibroTest using different cut-off values, we
will use the hierarchical summary ROC model (HSROC) to esti-
mate a summary ROC (SROC) curve (Macaskill 2010). If stud-
ies have reported a common cut-off value, we will use the bivari-
ate model (Macaskill 2010) to estimate summary sensitivity and
specificity.
For the studies reporting the results of both the index tests (Fi-
broTest plus transient elastography) on the same participants, we
will build the 2 × 2 tables for the combination of the two index
tests. We will consider as test negative all the participants negative
to both the FibroTest and transient elastography; we will consider
as test positive all the participants positive to at least one of the two
tests. We will use the positivity cut-off values for the FibroTest and
transient elastography used in the primary studies. If those cut-off
values are the same across studies, we will use the bivariate model
and we will provide the estimated summary sensitivity and speci-
ficity. In presence of heterogeneous cut-off values, we will perform
the meta-analysis using the HSROC model (Macaskill 2010).
For primary studies that report accuracy results for more than one
cut-off point, we will report sensitivities and specificities for all of
the cut-off points, but we will use a single cut-off point for each
study in HSROC (or bivariate model) analysis. We plan to base
the choice of the cut-off value on the most commonly reported
cut-off value for each stage of hepatic fibrosis depending on the
availability of data.
Comparison of the index tests
As descriptive preliminary analyses, we will plot studies in the
ROC space, differentiating the three index tests as suitable, us-
ing different colours or symbols. We plan to perform the formal
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comparative meta-analysis in an indirect way by adding the in-
dex tests as co-variates to the bivariate or HSROC model. For
direct comparisons, we will use the methods as described in the
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accu-
racy (Macaskill 2010)
One review author (GC) will perform all statistical analyses using
SAS statistical software, release 9.4 (SAS Institute Inc., Cary, NC,
USA).
Investigations of heterogeneity
To investigate sources of heterogeneity, we plan to add co-variates
(co-factors) to the bivariate or HSROC model as follows:
• liver biopsy as the reference standard: different grade of
inflammation according to the liver biopsy (below two grades
compared to two or greater grades of activity);
• different lengths of liver biopsy sample (less than 15 mm
compared to 15 mm or more);
• different number of portal tracts included in a liver biopsy
sample (fewer than seven compared to seven or more);
• different body mass indices (below 25 kg/m2 compared to
25 kg/m2 or more) (WHO 2014) (only relevant for the analyses
of studies in which transient elastography method was used);
• serum levels of ALT activity (up to the upper limit of
normal 40 IU/L compared to more than 40 IU/L) (only relevant
for the analyses of studies in which transient elastography
method was used).
Sensitivity analyses
We will perform sensitivity analyses by considering only cross-
sectional design studies (i.e., excluding case-control studies), and
studies assessed as low risk of bias (Appendix 2).
Assessment of reporting bias
We will not assess reporting bias as there is lack of sensitive tests,
suitable for investigation of reporting bias.
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F0 F0 F0 F0 F0
F1 F1 F1 F1 F1
F1 F1 F2 F1 F1
F2 F3 F3 F2 F2
F3 F3 F4 F2 F3
F4 F4 F5 F3 F4
F4 F4 F6 F4 F4
F: stage of hepatic fibrosis.
Stage* is an assessment of fibrosis location (i.e., scar). It is potentially irreversible. Stage describes only parenchymal location of collagen
and matrix deposition, and vascular/architectural alterations, but not absolute quantity (Kleiner 2012).
Table 2. Nonalcoholic Steatohepatitis Clinical Research Network scoring system for grade* of hepatic steatosis
Evaluation of parenchymal involvement by steatosis Steatosis grade
< 5% 0
5% to 33% 1
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Table 2. Nonalcoholic Steatohepatitis Clinical Research Network scoring system for grade* of hepatic steatosis (Continued)
34% to 66% 2
> 66% 3
*Grade is a global measure of hepatocellular and necroinflammatory injury; it describes amount and reflects features that are potentially
reversible (Kleiner 2012).
A P P E N D I C E S
Appendix 1. Search strategies
FibroScan, ultrasound impedance, magnetic resonance imaging (MRI) impedance
Database Time span Search strategy
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
Date will be given at review stage. ((transient elastograph* or fibroscan*) OR (fi-
brotest* or fibrosure*)) AND (hepatic or liver) and
(fibrosis or cirrhosis) AND liver biops*
The Cochrane Hepato-Biliary Group Di-
agnostic Test Accuracy Studies Register
Date will be given at review stage. ((transient elastograph* or fibroscan*) OR (fi-
brotest* or fibrosure*)) AND (hepatic or liver) and
(fibrosis or cirrhosis) AND liver biops*
Cochrane Central Register of Controlled
Trials (CENTRAL)
Latest issue. #1 MeSH descriptor: [Elasticity Imaging Tech-
niques] explode all trees
#2 (transient elastograph* or fibroscan*)
#3 (fibrotest* or fibrosure*)
#4 #1 or #2 or #3
#5 MeSH descriptor: [Liver Cirrhosis] explode all
trees
#6 (hepatic or liver) and (fibrosis or cirrhosis)
#7 #5 or #6
#8 MeSH descriptor: [Biopsy, Needle] explode all
trees
#9 liver biops*
#10 #8 or #9
#11 #4 and #7 and #10
MEDLINE (OvidSP) 1950 to the date of search. 1. exp Elasticity Imaging Techniques/
2. (transient elastograph* or fibroscan*).mp. [mp=
title, abstract, original title, name of substance
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(Continued)
word, subject heading word, keyword heading
word, protocol supplementary concept word, rare
disease supplementary concept word, unique iden-
tifier]
3. (fibrotest* or fibrosure*).mp. [mp=title, abstract,
original title, name of substance word, subject
heading word, keyword heading word, protocol
supplementary concept word, rare disease supple-
mentary concept word, unique identifier]
4. 1 or 2 or 3
5. exp Liver Cirrhosis/
6. ((hepatic or liver) and (fibrosis or cirrhosis)).
mp. [mp=title, abstract, original title, name of sub-
stance word, subject heading word, keyword head-
ing word, protocol supplementary concept word,
rare disease supplementary concept word, unique
identifier]
7. 5 or 6
8. exp Biopsy, Needle/
9. liver biops*.mp. [mp=title, abstract, original ti-
tle, name of substance word, subject heading word,
keyword heading word, protocol supplementary
concept word, rare disease supplementary concept
word, unique identifier]
10. 8 or 9
11. exp Hepatitis C, Chronic/
12. (chronic hepatitis c or hep C).mp. [mp=title,
abstract, original title, name of substance word,
subject heading word, keyword heading word, pro-
tocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
13. 11 or 12
14. 4 and 7 and 10 and 13
EMBASE (OvidSP) 1980 to the date of search. 1. exp elastography/
2. (transient elastograph* or fibroscan*).mp. [mp=
title, abstract, subject headings, headingword, drug
trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword]
3. (fibrotest* or fibrosure*).mp. [mp=title, abstract,
subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufac-
turer, device trade name, keyword]
4. 1 or 2 or 3
5. exp liver cirrhosis/
6. ((hepatic or liver) and (fibrosis or cirrhosis)).
mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device man-
ufacturer, drug manufacturer, device trade name,
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(Continued)
keyword]
7. 5 or 6
8. exp liver biopsy/
9. liver biops*.mp. [mp=title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, de-
vice trade name, keyword]
10. 8 or 9
11. exp hepatitis C/
12. (chronic hepatitis c or hep C).mp. [mp=ti-
tle, abstract, subject headings, heading word, drug
trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword]
13. 11 or 12
14. 4 and 7 and 10 and 13
Science Citation Index Expanded 1900 to the date of search. #7 879 #6 AND #5 AND #4 AND #3
#6 48,967 TS=(chronic hepatitis c or hep C)
#5 28,567 TS=(liver biops*)
#4 83,012 TS=((hepatic or liver) and (fibrosis or
cirrhosis))
#3 3,418 #2 OR #1
#2 613 TS=(fibrotest* or fibrosure*)
#1 3,091 TS=(transient elastograph* or fibroscan*)
Appendix 2. QUADAS-2
Domain Participant selection Index test Reference standard Flow and timing





use of index test, and
setting):
The studies that fulfil
the inclusion criteria of
this review should have
included participants of
any sex and ethnic ori-
gin, > 18 years old, and
diagnosed with chronic
hepatitis C. The partic-
ipants could have been
Describe the index test






phy method - no matter
the sequence of applica-
tion - for diagnosing fi-
brosis and cirrhosis, con-
ducted either before or
after liver biopsy
Describe the reference
standard and how it




the liver biopsy samples




or Brunt (see Table 1).
Describe any people
who did not receive the
index test(s) or refer-
ence standard (or both)
or who were excluded
from the 2 × 2 table
(refer to flow diagram)
: describe the time in-
terval and any inter-
ventions between in-
dex test(s) and refer-
ence standard:
We will exclude partici-
pants if the time interval
between diagnostic liver
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(Continued)
hospitalised or managed
as outpatients. The diag-
nosis of chronic hepati-
tis C in the study par-
ticipants had to be es-
tablished based on the
detection of both anti-
hepatitis C virus anti-
bodies and hepatitis C
virus ribonucleic acid in
the presence of biologi-
cal or histological signs
of chronic hepatitis
The participants could
have had any stage of fi-
brosis, including cirrho-
sis
Wewill not consider par-
ticipants who had re-
ceived a liver transplant
and with recurrent hep-
atitis C infection as well
as participants with ae-
tiologies of liver diseases
other than chronic hep-
atitis C virus infection
To ascertain the diagno-
sis of chronic hepatitis C
and study the presence
of cirrhosis, any or both





method) as well as the
reference standard had to
be performed, irrespec-
tive of the sequence
biopsy and any of the re-
view index tests is > 6
months
We will exclude partici-




data fromboth tests were




Was a consecutive or
random sample of par-
ticipants enrolled?
Yes: all consecutive par-
ticipants or random sam-
ple of people diagnosed
with chronic hepatitis
C were enrolled in the
study
Were the index test re-
sults interpreted with-
out knowledge of the






Is the reference stan-
dard likely to clas-
sify the target condi-
tion correctly?
Yes: if participants have
undergone liver biopsy
and the liver tissue spec-
imen was deemed ade-
quate for confident his-
Was there an appropri-
ate interval between in-
dex test(s) and refer-
ence standard?
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cient data were reported










phy method results were
interpreted with knowl-
edge of the results of the
liver biopsy
Unclear: insuffi-
cient data were reported
to permit a judgement
tological assessment
No: the liver tissue speci-
men was not deemed ad-
equate for confident his-
tological assessment
Unclear: insuffi-
cient data were reported
to permit a judgement
phy method and liver
biopsy was ≤ 6 months





phy method and liver
biopsy was > 6 months
Unclear: insuffi-
cient data were reported






sign was not avoided.
Unclear: insufficient in-
formation was reported
to permit a judgement




Unclear: it was not re-





edge of the results of
the index test?
Yes: liver biopsy results
were interpreted without
knowledge of the results
of the ultrasonography
test
No: liver biopsy results
were interpretedwith the




cient data were reported
to permit a judgement
Did all participants re-
ceive the reference stan-
dard?
Yes: all participants un-
derwent the reference
standard, liver biopsy
No: not all participants
underwent liver biopsy.
Unclear: insuffi-
cient data were reported
to permit a judgement
Did the study avoid in-
appropriate
exclusions?
Yes: the study avoided
inappropriate exclusions
(e.g., difficult to diag-
nose participants, failure
at liver biopsy, failure on
ultrasonography)
No: the study excluded
participants inappropri-
ately.
Did all participants re-
ceive the same reference
standard?
Yes: all participants re-
ceived the same refer-
ence standard, i.e., liver
biopsy
No: not all participants
received the same refer-
ence standard, i.e., liver
biopsy
Unclear: insuffi-
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(Continued)
Unclear: insuffi-
cient data were reported
to permit a judgement
cient data were reported
to permit a judgement
Were all participants




the selection criteria (se-
lected participants) were
included in the analysis,
or data on all the se-
lected participants were
available so that a 2 ×
2 table including all se-
lected participants could
be constructed
No: not all participants
meeting the selection cri-
teriawere included in the
analysis or the 2 × 2 table
could not be constructed
using data on all selected
participants
Unclear: insuffi-
cient data were reported
to permit a judgement
Risk of bias: high/low/
unclear
Could the selection of
participants have intro-
duced bias?
High risk of bias: if the




Low risk of bias: if the
answers to the 3 sig-
nalling questions on the
participant selection was
’yes’
Unclear risk of bias: if
the answers to the 3 sig-
nalling questions on the
participant selection was
either ’unclear’ or any
combination of ’unclear’
Could the conduct or
interpretation of the
index test have intro-
duced bias?
High risk of bias: if the
answer to any of the 2
signalling questions on
the conduct or interpre-
tation of the index test
was ’no’
Low risk of bias: if the
answer to the 2 signalling
questions on the conduct
or interpretation of the
index test was ’yes’
Unclear risk of bias: if
the answers to the 2
signalling questions on
the conduct or interpre-
Could
the reference standard,
its conduct, or its in-
terpretation have intro-
duced bias?
High risk of bias: if the
answer to any of the 2
signalling questions on
the reference standard,
its conduct, or its inter-
pretation was ’no’
Low risk of bias: if the
answer to the 2 signalling
questions on the refer-
ence standard, its con-
duct, or its interpreta-
tion was ’yes’
Unclear risk of bias: if




High risk of bias: if the
answer to any of the 4
signalling questions on
flow and timing was ’no’
Low risk of bias: if the
answer to the 4 signalling
questions on flow and
timing was ’yes’
Unclear risk of bias: if
the answers to the 4 sig-
nalling questions on flow
and timing was either
’unclear’ or any combi-
nation of ’unclear’ with
’yes’
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(Continued)
with ’yes’ tation of the index test
was either ’unclear’ or




its conduct, or its in-
terpretation was either
’unclear’ or any combi-





Are there concerns that
the included partici-
pants do not match the
review question?
High concern: there was
high concern that the in-
cluded participants did
not match the review
question
Low concern: there was
low concern that the in-
cluded participants did
not match the review
question
Unclear concern: if it was
unclear.
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
High concern: there was
high
concern that the conduct






from the way it is likely
to be used in clinical
practice
Low concern: there was
low concern that the
conduct or interpreta-
tion of the conduct or






from the way it is likely
to be used in clinical
practice
Unclear concern: if it was
unclear.
Are there concerns that
the target condition as
definedby the reference
standard did not match
the review question?
High concern: all partic-
ipants did not undergo
liver biopsy for cirrhosis
Low concern: all partic-
ipants underwent liver
biopsy for cirrhosis
If it was unclear.
--
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